<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1 INDICATIONS AND USAGE<BR>               <BR>                  These indications are based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with ADCETRIS.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        ADCETRIS is a CD30-directed antibody-drug conjugate indicated for:<BR><BR>                           <BR><BR>                        <BR>                        <BR>                           The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidatesÂ (1.1).  <BR>                           The treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen (1.2). <BR>                        <BR>                        These indications are based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with ADCETRIS.<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1 Hodgkin Lymphoma<BR>                     <BR>                        ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2 Systemic Anaplastic Large Cell Lymphoma<BR>                     <BR>                        ADCETRIS is indicated for treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>